This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Dexrabeprazole is a proton pump inhibitor indicated in the treatment of gastroesophageal reflux disease and gastrointestinal ulcers.
- Generic Name
- Dexrabeprazole
- DrugBank Accession Number
- DB13762
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Dexrabeprazole (DB13762)
- Weight
- Average: 359.443
Monoisotopic: 359.130362243 - Chemical Formula
- C18H21N3O3S
- Synonyms
- Rabeprazole, (r)-
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Duodenal ulcer •••••••••••• Adjunct therapy in treatment of Gastric ulcer helicobacter •••••••••••• Used in combination for symptomatic treatment of Gastro-esophageal reflux disease (gerd) Combination Product in combination with: Domperidone (DB01184) •••••••••••• ••••••• Treatment of Gastro-esophageal reflux disease (gerd) •••••••••••• Treatment of Benign gastric ulcers •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The metabolism of Dexrabeprazole can be increased when combined with Abatacept. Abrocitinib The metabolism of Abrocitinib can be decreased when combined with Dexrabeprazole. Acenocoumarol The metabolism of Dexrabeprazole can be decreased when combined with Acenocoumarol. Adalimumab The metabolism of Dexrabeprazole can be increased when combined with Adalimumab. Albendazole The metabolism of Dexrabeprazole can be decreased when combined with Albendazole. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DEXRIDON MR 30/10 MG KAPSÜL ,30 KAPSÜL Dexrabeprazole (10 mg) + Domperidone (30 mg) Capsule Oral CELTİS İLAÇ SAN. VE TİC. A.Ş. 2014-01-08 Not applicable Turkey 
Categories
- ATC Codes
- A02BC07 — Dexrabeprazole
- Drug Categories
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Acid Reducers
- Alimentary Tract and Metabolism
- Anti-Ulcer Agents
- Benzimidazoles
- Cytochrome P-450 CYP2C19 Substrates
- Cytochrome P-450 Substrates
- Drugs for Acid Related Disorders
- Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
- Enzyme Inhibitors
- Gastric Acid Lowering Agents
- Gastrointestinal Agents
- Heterocyclic Compounds, Fused-Ring
- Proton Pump Inhibitors
- Pyridines
- Sulfoxides
- Sulfur Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzimidazoles
- Sub Class
- Sulfinylbenzimidazoles
- Direct Parent
- Sulfinylbenzimidazoles
- Alternative Parents
- Methylpyridines / Alkyl aryl ethers / Benzenoids / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Dialkyl ethers / Azacyclic compounds / Organonitrogen compounds show 2 more
- Substituents
- Alkyl aryl ether / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative / Imidazole show 11 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 65JK8810RM
- CAS number
- 177795-60-7
- InChI Key
- YREYEVIYCVEVJK-RUZDIDTESA-N
- InChI
- InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)/t25-/m1/s1
- IUPAC Name
- 2-[(R)-[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl]-1H-1,3-benzodiazole
- SMILES
- COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=CC=CC=C3N2)=C1C
References
- General References
- TITCK Product Information: RABBY-D (dexrabeprazole sodium) oral enteric coated tablet [Link]
- External Links
- ChemSpider
- 8082507
- BindingDB
- 50409892
- ChEBI
- 134729
- ChEMBL
- CHEMBL1615209
- ZINC
- ZINC000001530935
- PDBe Ligand
- RZX
- PDB Entries
- 3pgl
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Treatment Gastro-esophageal Reflux Disease (GERD) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule 25 mg Capsule Oral Tablet, delayed release Oral 10 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.336 mg/mL ALOGPS logP 2.04 ALOGPS logP 2.09 Chemaxon logS -3 ALOGPS pKa (Strongest Acidic) 9.35 Chemaxon pKa (Strongest Basic) 4.24 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 77.1 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 98.07 m3·mol-1 Chemaxon Polarizability 39.48 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0019000000-7bf6bec21410dcb8d1ac Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0809000000-256e447c7b3a8f1b4d29 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-01t9-2859000000-80ca0f17393d1408c4bd Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00lr-0719000000-b09c9b8f5a43cf03998f Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0900000000-9fdf28fafa11fd164128 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-3962000000-729add7b88ba63c9c447 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 195.7847783 predictedDarkChem Lite v0.1.0 [M-H]- 186.51445 predictedDeepCCS 1.0 (2019) [M+H]+ 196.8699783 predictedDarkChem Lite v0.1.0 [M+H]+ 189.00362 predictedDeepCCS 1.0 (2019) [M+Na]+ 196.1505783 predictedDarkChem Lite v0.1.0 [M+Na]+ 196.72237 predictedDeepCCS 1.0 (2019)
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) (PubMed:18577768, PubMed:19965576, PubMed:20972997). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18577768, PubMed:19965576, PubMed:20972997). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates PUFA specifically at the omega-1 position (PubMed:18577768). Catalyzes the epoxidation of double bonds of PUFA (PubMed:19965576, PubMed:20972997). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Hydroxylates fenbendazole at the 4' position (PubMed:23959307)
- Specific Function
- (R)-limonene 6-monooxygenase activity
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55944.565 Da
References
Drug created at June 23, 2017 20:48 / Updated at May 22, 2021 06:01